Institute of Biomedical Engineering, University of Toronto, Toronto, ON, Canada.
Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, ON, Canada.
Methods Mol Biol. 2022;2485:175-190. doi: 10.1007/978-1-0716-2261-2_12.
Extensive progress has been made in developing engineered models for elucidating human cardiac disease. Cardiac fibrosis is often associated with all forms of cardiac disease and has a direct deleterious effect on cardiac function. As currently there is no effective therapeutic strategy specifically designed to target fibrosis, in vitro diagnostic platforms for drug testing have generated significant interest. In this context, we have developed an innovative approach to generate human cardiac fibrotic tissues on Biowire II platform and established a compound screening system. The disease model is constructed to recapitulate contractile, biomechanical, and electrophysiological complexities of fibrotic myocardium. Additionally, an integrated model with fibrotic and healthy cardiac tissues coupled together can be created to mimic focal fibrosis. The methods for constructing the Biowire fibrotic model will be described here.
在开发用于阐明人类心脏疾病的工程模型方面已经取得了广泛的进展。心脏纤维化通常与所有形式的心脏疾病相关，并对心脏功能有直接的有害影响。由于目前没有专门针对纤维化的有效治疗策略，用于药物测试的体外诊断平台引起了极大的兴趣。在这种情况下，我们开发了一种在 Biowire II 平台上生成人类心脏纤维化组织的创新方法，并建立了一个化合物筛选系统。该疾病模型的构建旨在重现纤维化心肌的收缩、生物力学和电生理复杂性。此外，还可以创建一个与纤维化和健康心脏组织相结合的综合模型，以模拟局灶性纤维化。这里将描述构建 Biowire 纤维化模型的方法。
